
Sign up to save your podcasts
Or


By Dr Richie Abel (PhD) and Prof David Armstrong (MD)
5
55 ratings
The podcast currently has 40 episodes available.
The most played episodes among Podcast App listeners.

The lads jetted off to sunny Girona for the European Calcified Tissue Society Congress, where they caught up with some brilliant boneheads about the latest in bone research. In Part 2, we chat to Stuart Ralston about the TOPAZ trial for Brittle Bone Disease, Emma Duncan about the ASBMR and ECTS Societies and Kass Javaid about his conference highlights.

The lads jetted off to sunny Girona for the European Calcified Tissue Society Congress, where they caught up with some brilliant boneheads about the latest in bone research. In Part 3, we chat to Friederike Schulte about combining physical loading with bone drugs, Mathilde Palmier about steroids weakening bone-building cells, and Melina Guillon about repurposing drugs for osteoporosis.

The lads jetted off to sunny Girona for the European Calcified Tissue Society Congress, where they caught up with some brilliant boneheads about the latest in bone research. In Part 1, we chat to Louise Thomas about bone marrow fat and bone health, Bram van der Eerden about new bone model technologies that could help replace animals in research, Victoria Chatzimavridou about radiotherapy and insufficiency fractures, and Jelena Jadzic about her prize-winning work on alcohol-associated liver disease and vertebral fractures.

The lads talked to Professor Roland Baron from Harvard University. Roland has played a key role in characterising bone signalling pathways that govern bone formation and contributed to developing new treatments that increase cell signalling to improve bone mass. Roland is a co-founder and chair of the International Federation of Musculoskeletal Research Societies supporting our community and helping young scientists from the entire world to develop and support people living with osteoporosis.

The lads talked to each other about the exciting news that the National Institute for Health and Care Excellence (Nice) announced it had approved a new drug, Abaloparatide, for use by the health service. It will be available for use on the NHS in England within three months.
The podcast currently has 40 episodes available.

3,005 Listeners

5 Listeners